512529 logo

Viyash Scientific Limited Stock Price

BSE:512529 Community·₹110.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

512529 Share Price Performance

₹0
-175.60 (-100.00%)
₹319.75
Fair Value
₹0
-175.60 (-100.00%)
Price ₹0

512529 Community Narratives

·
Fair Value ₹319.75 21.0% undervalued intrinsic discount

CDMO And Animal Health Expansion Will Shape A Stronger Long Term Earnings Profile

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

512529 logo

512529: Governance Resolutions And Investor Day Will Support Future Bullish Repricing

Fair Value: ₹319.75 21.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
4 Rewards

Viyash Scientific Limited Key Details

₹35.8b

Revenue

₹17.0b

Cost of Revenue

₹18.7b

Gross Profit

₹16.6b

Other Expenses

₹2.1b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
4.84
52.33%
5.91%
15.7%
View Full Analysis

About 512529

Founded
1985
Employees
2900
CEO
Hari Bodepudi
WebsiteView website
www.viyash.com

Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.

Recent 512529 News & Updates

Narrative Update Aug 13

512529: Governance Resolutions And Investor Day Will Support Future Bullish Repricing

Analysts have lifted their fair value estimate for Viyash Scientific from ₹300 to about ₹319.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a future P/E of roughly 29.71x. What’s in the News for Viyash Scientific Board meeting scheduled on Aug 11, 2026 at 11:30 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026, and to consider other matters.

Recent updates

No updates